Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement

Journal of Rheumatology

Volumn 40, Issue 5, 2013, Pages 617-623

  Johnson, Beverly K ^a   Goodman, Susan M ^a   Alexiades, Michael M ^a   Figgie, Mark P ^a   Demmer, Ryan T ^b   Mandl, Lisa A ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b Department of Medicine   (United States)

Author keywords

Arthroplasty; Infection; Rheumatoid arthritis; Surgery; Tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROCORTISONE; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE DURATION; DISEASE EXACERBATION; DRUG HALF LIFE; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUESTIONNAIRE; REOPERATION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SELF REPORT; SURGICAL INFECTION; TOTAL KNEE REPLACEMENT; WOUND HEALING;

ARTHROPLASTY; INFECTION; RHEUMATOID ARTHRITIS; SURGERY; TUMOR NECROSIS FACTOR INHIBITORS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROPLASTY, REPLACEMENT, KNEE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PERIOPERATIVE CARE; QUALITY OF LIFE; QUESTIONNAIRES; RECOVERY OF FUNCTION; REGISTRIES; REOPERATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURGICAL WOUND INFECTION; SYMPTOM ASSESSMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876940337     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121171     Document Type: Article

References (44)

1. Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005;52:1009-19. (Pubitemid 40530106)
2. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904. (Pubitemid 47502735)
3. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33. (Pubitemid 46608637)
4. Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1713-20.
5. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials. Arthritis Rheum 2011;63:1479-85.
6. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
7. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754-64. (Pubitemid 47110375)
8. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:628-34. (Pubitemid 43228641)
9. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12. (Pubitemid 41612206)
10. Momohara S, Kawakami K, Iwamoto T, Yano K, Sakuma Y, Hiroshima R, et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 2011;21:469-75.
11. Kubota A, Nakamura T, Miyazaki Y, Sekiguchi M, Suguro T. Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. Mod Rheumatol 2012;22:844-8.
12. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55:333-7.
13. Kawakami K, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, Yano K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: Perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology 2010;49:341-7.
14. Ryan BM, Romberg M, Wolters F, Stockbrugger RW. Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction. Eur J Gastroenterol Hepatol 2004;16:941-2. (Pubitemid 39179668)
15. Grange L, Nissen MJ, Garambois K, Dumolard A, Duc C, Gaudin P, et al. Infliximab-induced cerebral thrombophlebitis. Rheumatology 2005;44:260-1.
16. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. (Pubitemid 351847559)
17. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 2010;49:2217-9.
18. Reumatologie NVv. Medicijnen: het toepassen van TNF blockade in de behandeling vav reumatoide arthritis [in Dutch]. Medications: Use of TNF blockade in the treatment of rheumatoid arthritis. Utrecht: Dutch Society for Rheumatology; 2003.
19. Pham T, Claudepierre P, Deprez X, Fautrel B, Goupille P, Hilliquin P, et al. Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Societe Francaise de Rhumatologie, SFR). Joint Bone Spine 2005;72 Suppl 1:S1-58.
20. Hayata K, Kanbe K, Chiba J, Nakamura A, Inoue Y, Hobo K. Clinical factors related to the efficacy and complications of orthopedic surgery for rheumatoid arthritis with infliximab. Int J Rheum Dis 2011;14:31-6.
21. Wendling D, Balblanc JC, Brousse A, Lohse A, Lehuede G, Garbuio P, et al. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: An observational study on 50 surgical procedures. Ann Rheum Dis 2005;64:1378-9. (Pubitemid 41206266)
22. Talwalkar SC, Grennan DM, Gray J, Johnson P, Hayton MJ. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 2005;64:650-1. (Pubitemid 40469105)
23. Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 2007;25:430-6.
24. den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: A large retrospective study. J Rheumatol 2007;34:689-95.
25. Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Kida D, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol 2010;29:495-500.
26. Gilson M, Gossec L, Mariette X, Gherissi D, Guyot MH, Berthelot JM, et al. Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor alpha-blockers: A case-control study. Arthritis Res Ther 2010;12:R145.
27. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004;25:331-5. (Pubitemid 39096154)
28. Schrama JC, Espehaug B, Hallan G, Engesaeter LB, Furnes O, Havelin LI, et al. Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: A prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplasty Register. Arthritis Care Res 2010;62:473-9.
29. Osnes-Ringen H, Kvien TK, Henriksen JE, Mowinckel P, Dagfinrud H. Orthopaedic surgery in 255 patients with inflammatory arthropathies: Longitudinal effects on pain, physical function and health-related quality of life. Ann Rheum Dis 2009;68:1596-601.
30. EuroQol - A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
31. Southern DA, Quan H, Ghali WA. Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care 2004;42:355-60.
32. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987;40:373-83. (Pubitemid 17055592)
33. Sharabiani MT, Aylin P, Bottle A. Systematic review of comorbidity indices for administrative data. Med Care 2012;50:1109-18.
34. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27. (Pubitemid 128456396)
35. Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl. 2005 Mar;74:13-8. (Pubitemid 40365775)
36. Nestorov I. Clinical pharmacokinetics of TNF antagonists: How do they differ? Semin Arthritis Rheum 2005;34 Suppl:12-8.
37. Goh L, Jewell T, Laversuch C, Samanta A. Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol Int 2012;32:5-13.
38. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306:2331-9.
39. Consensus paper on the surveillance of surgical wound infections. The Society for Hospital Epidemiology of America; The Association for Practitioners in Infection Control; The Centers for Disease Control; The Surgical Infection Society. Infect Control Hosp Epidemiol 1992;13:599-605.
40. Pappas DA, Giles JT. Do antitumor necrosis factor agents increase the risk of postoperative orthopedic infections? Curr Opin Rheumatol 2008;20:450-6.
41. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
42. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011;13:R32.
43. Carroll RJ, Thompson WK, Eyler AE, Mandelin AM, Cai T, Zink RM, et al. Portability of an algorithm to identify rheumatoid arthritis in electronic health records. J Am Med Inform Assoc 2012;19:e162-9.
44. Liao KP, Cai T, Gainer V, Goryachev S, Zeng-Treitler Q, Raychaudhuri S, et al. Electronic medical records for discovery research in rheumatoid arthritis. Arthritis Care Res 2010;62:1120-7.